145 related articles for article (PubMed ID: 2013215)
1. Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases.
Bauernfeind A
Diagn Microbiol Infect Dis; 1991; 14(1):89-92. PubMed ID: 2013215
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
Bauernfeind A; Jungwirth R
Infection; 1991; 19(5):353-62. PubMed ID: 1800377
[TBL] [Abstract][Full Text] [Related]
3. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
Wise R; Andrews JM; Ashby JP; Thornber D
Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
[TBL] [Abstract][Full Text] [Related]
4. Third generation oral cephalosporins: comparative in vitro kinetics.
Speciale A; Blandino G; Nicoletti G
J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
[TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.
Bauernfeind A
Diagn Microbiol Infect Dis; 1991; 14(1):63-74. PubMed ID: 2013211
[TBL] [Abstract][Full Text] [Related]
6. [Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].
Philippon A; Jarlier V; Legrand P; Fournier G; Nicolas MH; Duval J
Presse Med; 1989 Oct; 18(32):1560-6. PubMed ID: 2530532
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis.
Doern GV
Diagn Microbiol Infect Dis; 1991; 14(1):75-7. PubMed ID: 1901536
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720)--a review of United States and Canadian results.
Jones RN
Diagn Microbiol Infect Dis; 1991; 14(1):37-43. PubMed ID: 2013209
[TBL] [Abstract][Full Text] [Related]
9. [Effect of broad spectrum beta-lactamases on in vitro sensitivity of clinical isolates of Klebsiella pneumoniae to oral cephalosporins].
Bedenić B; Singer S
Lijec Vjesn; 2000; 122(1-2):8-13. PubMed ID: 10916350
[TBL] [Abstract][Full Text] [Related]
10. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
Medeiros AA; Crellin J
Pediatr Infect Dis J; 1997 Mar; 16(3 Suppl):S49-55. PubMed ID: 9076836
[TBL] [Abstract][Full Text] [Related]
11. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].
Bauernfeind A; Jungwirth R; Schweighart S; Theopold M
Infection; 1990; 18 Suppl 3():S155-67. PubMed ID: 2079378
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
Doern GV; Vautour R
Diagn Microbiol Infect Dis; 1992; 15(7):633-40. PubMed ID: 1424521
[TBL] [Abstract][Full Text] [Related]
13. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers.
Dan M; Poch F; Edelman A; Asherov J; Hafely H; Atzmon Y
J Antimicrob Chemother; 1998 Apr; 41(4):485-8. PubMed ID: 9598780
[TBL] [Abstract][Full Text] [Related]
14. [Comparative antibacterial activity of ceftibuten (SH 39 720) against 150 K. pneumoniae strains producing different beta-lactamases].
Thabaut A; Meyran M
Pathol Biol (Paris); 1990 May; 38(5):347-51. PubMed ID: 2195446
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid.
Arguedas AG; Arrieta AC; Stutman HR; Akaniro JC; Marks MI
J Antimicrob Chemother; 1991 Mar; 27(3):311-8. PubMed ID: 1903788
[TBL] [Abstract][Full Text] [Related]
16. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies.
Sirot J; Chanal C; Petit A; Sirot D; Labia R; Gerbaud G
Rev Infect Dis; 1988; 10(4):850-9. PubMed ID: 3055177
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic activity of five oral cephalosporins against Haemophilus influenzae.
Stein GE; Schooley S; Walker RD; Strenkoski-Nix L
Pharmacotherapy; 1997; 17(2):235-41. PubMed ID: 9085313
[TBL] [Abstract][Full Text] [Related]
18. Ceftibuten--in-vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action.
Wise R; Andrews JM; Ashby JP; Thornber D
J Antimicrob Chemother; 1990 Aug; 26(2):209-13. PubMed ID: 2120175
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
Jones RN; Barry AL
Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
[TBL] [Abstract][Full Text] [Related]
20. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
Bedenic B; Vranes J; Suto S; Zagar Z
Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
